CN1976921B - (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形 - Google Patents

(3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形 Download PDF

Info

Publication number
CN1976921B
CN1976921B CN2005800215163A CN200580021516A CN1976921B CN 1976921 B CN1976921 B CN 1976921B CN 2005800215163 A CN2005800215163 A CN 2005800215163A CN 200580021516 A CN200580021516 A CN 200580021516A CN 1976921 B CN1976921 B CN 1976921B
Authority
CN
China
Prior art keywords
methyl
trimethylammonium
tryptophyl
phenmethyl
hydrazides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800215163A
Other languages
English (en)
Chinese (zh)
Other versions
CN1976921A (zh
Inventor
基思·洛里默
西蒙·H·派因斯
贝恩哈德·保罗
本亚明·利特勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Albany Molecular Research Inc
Sapphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Research Inc, Sapphire Therapeutics Inc filed Critical Albany Molecular Research Inc
Priority to CN201110251236.9A priority Critical patent/CN102584937B/zh
Publication of CN1976921A publication Critical patent/CN1976921A/zh
Application granted granted Critical
Publication of CN1976921B publication Critical patent/CN1976921B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN2005800215163A 2004-06-29 2005-06-22 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形 Expired - Lifetime CN1976921B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110251236.9A CN102584937B (zh) 2004-06-29 2005-06-22 (3r)‑1‑(2‑甲基丙氨酰‑d‑色氨酰)‑3‑(苯甲基)‑3‑哌啶羧酸1，2，2‑三甲基酰肼的晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58375704P 2004-06-29 2004-06-29
US60/583,757 2004-06-29
PCT/US2005/022408 WO2006016995A1 (en) 2004-06-29 2005-06-22 Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201310308801.XA Division CN103772483A (zh) 2004-06-29 2005-06-22 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形
CN201110251236.9A Division CN102584937B (zh) 2004-06-29 2005-06-22 (3r)‑1‑(2‑甲基丙氨酰‑d‑色氨酰)‑3‑(苯甲基)‑3‑哌啶羧酸1，2，2‑三甲基酰肼的晶形

Publications (2)

Publication Number Publication Date
CN1976921A CN1976921A (zh) 2007-06-06
CN1976921B true CN1976921B (zh) 2013-08-21

Family

ID=35064648

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2005800215163A Expired - Lifetime CN1976921B (zh) 2004-06-29 2005-06-22 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
CN201110251236.9A Expired - Lifetime CN102584937B (zh) 2004-06-29 2005-06-22 (3r)‑1‑(2‑甲基丙氨酰‑d‑色氨酰)‑3‑(苯甲基)‑3‑哌啶羧酸1，2，2‑三甲基酰肼的晶形
CN201310308801.XA Pending CN103772483A (zh) 2004-06-29 2005-06-22 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201110251236.9A Expired - Lifetime CN102584937B (zh) 2004-06-29 2005-06-22 (3r)‑1‑(2‑甲基丙氨酰‑d‑色氨酰)‑3‑(苯甲基)‑3‑哌啶羧酸1，2，2‑三甲基酰肼的晶形
CN201310308801.XA Pending CN103772483A (zh) 2004-06-29 2005-06-22 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形

Country Status (9)

Country Link
US (2) US7825138B2 (https=)
EP (2) EP2298760B1 (https=)
JP (2) JP5122950B2 (https=)
KR (1) KR101324340B1 (https=)
CN (3) CN1976921B (https=)
CA (1) CA2572325C (https=)
IL (1) IL180336A0 (https=)
MX (1) MXPA06015003A (https=)
WO (1) WO2006016995A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
SI2958916T1 (sl) * 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
GEP20186939B (en) * 2014-09-04 2018-12-25 Healthcare Sa Helsinn Medical treatments based on anamorelin
WO2017067438A1 (zh) * 2015-10-20 2017-04-27 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法
US9837965B1 (en) 2016-09-16 2017-12-05 Peregrine Semiconductor Corporation Standby voltage condition for fast RF amplifier bias recovery
BR112022002767A2 (pt) 2019-08-30 2022-05-10 Helsinn Healthcare Sa Métodos de fabricação de um comprimido de cloridrato de anamorelina, comprimidos e método para melhorar um ou mais sintomas de caquexia de câncer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL322706A1 (en) * 1993-11-09 1998-02-16 Merck & Co Inc Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
WO1998003473A1 (en) * 1996-07-22 1998-01-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
IL137007A0 (en) * 1998-01-16 2001-06-14 Novo Nordisk As Compounds with growth hormone releasing properties
PT1077941E (pt) * 1998-05-11 2010-07-01 Novo Nordisk As Compostos com propriedades de libertaã†o da hormona de crescimento
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
KR20070010151A (ko) * 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties

Also Published As

Publication number Publication date
CA2572325A1 (en) 2006-02-16
CN1976921A (zh) 2007-06-06
EP2298760B1 (en) 2015-08-05
IL180336A0 (en) 2007-07-04
JP2008505078A (ja) 2008-02-21
HK1105000A1 (en) 2008-02-01
JP5122950B2 (ja) 2013-01-16
KR20070030222A (ko) 2007-03-15
US20070004638A1 (en) 2007-01-04
EP1768976B1 (en) 2017-04-26
US7825138B2 (en) 2010-11-02
CA2572325C (en) 2013-08-27
US8466173B2 (en) 2013-06-18
US20110003996A1 (en) 2011-01-06
MXPA06015003A (es) 2007-08-07
JP2012188452A (ja) 2012-10-04
JP5718286B2 (ja) 2015-05-13
CN103772483A (zh) 2014-05-07
CN102584937B (zh) 2017-03-01
WO2006016995A1 (en) 2006-02-16
CN102584937A (zh) 2012-07-18
KR101324340B1 (ko) 2013-10-31
EP2298760A1 (en) 2011-03-23
EP1768976A1 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
US10519120B2 (en) Crystal modifications of elobixibat
CN107400134A (zh) 嘌呤衍生物的结晶形式
JP2022550374A (ja) テルフェニル化合物の新規な塩
JP5718286B2 (ja) （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形
EP2635580B1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
EA025358B1 (ru) N-(5S,6S,9R)-5-АМИНО-6-(2,3-ДИФТОРФЕНИЛ)-6,7,8,9-ТЕТРАГИДРО-5H-ЦИКЛОГЕПТА[b]ПИРИДИН-9-ИЛ-4-(2-ОКСО-2,3-ДИГИДРО-1H-ИМИДАЗО[4,5-b]ПИРИДИН-1-ИЛ)ПИПЕРИДИН-1-КАРБОКСИЛАТНАЯ СОЛЬ
UA125516C2 (uk) Заміщені діазагетеробіциклічні сполуки та їх застосування
CN108884080A (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
JP2023024729A (ja) ヤヌスキナーゼ阻害剤の結晶形
JP2022000451A (ja) ピリジノイルピペリジン５−ｈｔ１ｆアゴニストに関する組成物および方法
KR20130023218A (ko) 새로운 다형체
US11466008B2 (en) Co-crystals of neflamapimod (VX-745)
US9975921B2 (en) Crystal forms of anamorelin
AU2005272074B2 (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
TWI853707B (zh) 萘并呋喃取代的戊二醯亞胺類化合物的晶型、製備方法及其應用
HK1105000B (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1, 2, 2-trimethylhydrazide
HK1197827A (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20220087430A (ko) N-tert-부틸-4[[2-(5-클로로-2-하이드록시-페닐)아세틸]아미노]피리딘-2-카르복사미드의 고체 형태
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105000

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: LANBAOSHI THERAPEUTIC INC.; APPLICANT

Free format text: FORMER OWNER: LANBAOSHI THERAPEUTIC INC.

Effective date: 20080314

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080314

Address after: New jersey, USA

Applicant after: SAPPHIRE THERAPEUTICS, Inc.

Co-applicant after: ALBANY MOLECULE INSTITUTE

Address before: New jersey, USA

Applicant before: SAPPHIRE THERAPEUTICS, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1105000

Country of ref document: HK

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: ALBANY MOLECULAR RESEARCH INC.

Effective date: 20140403

Owner name: HELSINN HEALTHCARE SA

Free format text: FORMER OWNER: SAPPHIRE THERAPEUTICS INC.

Effective date: 20140403

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140403

Address after: Lugano Switzerland / bazzero

Patentee after: HELSINN HEALTHCARE S.A.

Address before: Delaware

Patentee before: HELSINN THERAPEUTICS (U.S.), Inc.

Effective date of registration: 20140403

Address after: Delaware

Patentee after: HELSINN THERAPEUTICS (U.S.), Inc.

Address before: Delaware

Patentee before: HELSINN THERAPEUTICS (U.S.), Inc.

Patentee before: Albany Molecule Institute

Effective date of registration: 20140403

Address after: Delaware

Patentee after: HELSINN THERAPEUTICS (U.S.), Inc.

Patentee after: ALBANY MOLECULE INSTITUTE

Address before: New jersey, USA

Patentee before: SAPPHIRE THERAPEUTICS, Inc.

Patentee before: Albany Molecule Institute

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Lugano Switzerland / bazzero

Patentee after: HELSINN HEALTHCARE S.A.

Address before: Lugano Switzerland / bazzero

Patentee before: HELSINN HEALTHCARE S.A.

CX01 Expiry of patent term

Granted publication date: 20130821

CX01 Expiry of patent term